News & media


02 February 2017

CALCISCON has moved to Biel

As of 2.2.2017 Calciscon has moved to Biel, InnoCampus (Aarbergstrasse 5, 2560 Nidau). There is now more space available to create the future and a successful business.


17 September 2016

«…dann haben Millionen von Patienten ein besseres Leben»

Interview mit A.Pasch, CEO CALCISCON AG, in der Zeitung "Der Bund", Bern.


14 September 2016

CALCISCON is among the Top 100 Start-Ups 2016

Complete List


15 January 2016

CALCISCON is ISO 13485 certified

After successful implementation of its quality management system, CALCISCON has received ISO 13485:2003 and EN ISO 13485:2012 certification in December 2015. 


16 September 2015

CALCISCON again among the Top 100 Swiss Startups

Calciscon was ranked 41 among the Top 100 Swiss Startups chosen by startup.ch in 2015.


31 July 2015

Inselspital Bern launches T50-Test

The Department of Clinical Chemistry of the University Hospital Bern (Inselspital), launches CALCISCON's T50-Test for official clinical use for patients. The Inselspital info flyer can be downloaded here.


10 July 2015

CE-marked T50-Test kit available

CALCISCON launches as its first product the CE-certified T50-Test kit. 


23 March 2015

CALCISCON closes Series A financing round

CALCISCON closes a series A financing round. This will enable the company to develop and launch its CE-marked T50-Test kit in 2015 in Europe.


01 December 2014

Prof. Geoffrey A. Block joins Medical Advisory Board

We are delighted that Prof. Geoffrey Block joined CALCISCON's Medical Advisory Board ....read more.


17 September 2014

CALCISCON is a Swiss Top 100 startup company

Startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung. CALCISCON took part in this prestigious competition for the first time in 2014 and was selected as a top 100 startup on the 38th place. 


18 June 2014

CALCISCON wins de Vigier entrepreneurship prize

For this year's Swiss entrepreneur prize of the W.A. de Vigier foundation 250 projects were competing. CALCISCON was selected as one of the five winners and received CHF 100,000…. read more 


02 June 2014

T50 test predicts survival of kidney transplanted patients

In a recently published abstract at the international ERA-EDTA Congress in Amsterdam, Keyzer et al. showed in 700 kidney transplanted patients that serum T50 is associated with mortality and graft failure…. read more


07 April 2014 

CALCISCON wins venture kick III entrepreneurship prize

CALCISCON wins the prestigious venture kick competition (www.venturekick.ch) and receives CHF 130,000. ...read more.... 


01 March 2014 

CALCISCON moves into labs at University Hospital Bern

CALCISCON starts its operational business in lab facilities located within the central clinical lab of University Hospital Bern, Inselspital.


18 January 2014

CALCISCON establishes medical & scientific advisory board

Leading experts in the fields of clinical and basic biomineralization research join the newly established advisory board at CALCISCON...read more...


03 December 2013

CALCISCON wins the Heuberger Winterthur entrepreneurship award 

CALCISCON wins CHF 150,000. In total, 133 projects were in competion for one of the three prestigious prizes donated by the Robert and Ruth Heuberger Foundation.  


31 October 2013

T50-Test predicts survival of chronic kidney disease patients

A recently published study (Smith et al., JASN 2014) shows a close association between T50-Test and survival of CKD 3&4 patients.  One hundred and eighty patients were analysed in this prospective study over 5.3 years.